Literature DB >> 18564361

Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis.

Tiemo Katzenberger1, Dirk Kienle, Stephan Stilgenbauer, Sylvia Höller, Carolin Schilling, Uwe Mäder, Bernhard Puppe, Celine Petzoldt, Sandrine Sander, Lars Bullinger, Heike Stöcklein, Jörg Kalla, Elena Hartmann, Patrick Adam, M Michaela Ott, Hans-Konrad Müller-Hermelink, Andreas Rosenwald, German Ott.   

Abstract

Mantle cell lymphoma (MCL) is an aggressive lymphoid tumour characterized by the translocation t(11;14)(q13;q32) and a poor clinical outcome (median survival: 3-4 years). Recent studies revealed that increased proliferation of the tumour cells and certain chromosomal aberrations, such as deletions of 17p13 and 9p21 represent major adverse biological markers in this disease, although the molecular targets of chromosomal imbalances in MCL have not been identified for the large majority of loci affected. To correlate histomorphological and proliferation features of MCL with genetic findings, we investigated 223 MCL by fluorescence in situ hybridization (FISH) (n = 157) and/or classical cytogenetic banding analysis (n = 129). FISH analysis turned out to be distinctly more sensitive in the delineation of aberrations. Complex karyotypic alterations were associated with higher proliferation indices and inferior prognosis. A comprehensive analysis of biological features including genetic alterations in MCL by hierarchical clustering resulted in the delineation of four tumour subgroups differing with respect to their genetic constitution and suggesting different transformation or progression pathways. Moreover, in one of the groups identified, a more indolent clinical behaviour was associated with few secondary aberrations and fewer known high-risk chromosomal aberrations, which points to the importance of the quality of karyotypic evolution in MCL tumours.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18564361     DOI: 10.1111/j.1365-2141.2008.07199.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

Authors:  Ana Mozos; Cristina Royo; Elena Hartmann; Daphne De Jong; Cristina Baró; Alexandra Valera; Kai Fu; Dennis D Weisenburger; Jan Delabie; Shih-Sung Chuang; Elaine S Jaffe; Carmen Ruiz-Marcellan; Sandeep Dave; Lisa Rimsza; Rita Braziel; Randy D Gascoyne; Francisco Solé; Armando López-Guillermo; Dolors Colomer; Louis M Staudt; Andreas Rosenwald; German Ott; Pedro Jares; Elias Campo
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

Review 2.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

Review 3.  Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.

Authors:  Adalgisa Condoluci; Davide Rossi; Emanuele Zucca; Franco Cavalli
Journal:  Curr Oncol Rep       Date:  2018-08-22       Impact factor: 5.075

4.  TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.

Authors:  Hua-Jie Dong; Li-Tao Zhou; Cheng Fang; Lei Fan; Dan-Xia Zhu; Yin-Hua Wang; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2011-11-06       Impact factor: 3.064

5.  Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.

Authors:  Mathieu Gallo; Valère Cacheux; Laure Vincent; Caroline Bret; Ariane Tempier; Caroline Guittard; Alexandra Macé; Nicolas Leventoux; Valérie Costes; Vanessa Szablewski
Journal:  Virchows Arch       Date:  2016-09-07       Impact factor: 4.064

6.  Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

Authors:  I Brian Greenwell; Ashley D Staton; Michael J Lee; Jeffrey M Switchenko; Debra F Saxe; Joseph J Maly; Kristie A Blum; Natalie S Grover; Stephanie P Mathews; Max J Gordon; Alexey V Danilov; Narendranath Epperla; Timothy S Fenske; Mehdi Hamadani; Steven I Park; Christopher R Flowers; Jonathon B Cohen
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

7.  Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.

Authors:  Elena M Hartmann; Elias Campo; George Wright; Georg Lenz; Itziar Salaverria; Pedro Jares; Wenming Xiao; Rita M Braziel; Lisa M Rimsza; Wing-Chung Chan; Dennis D Weisenburger; Jan Delabie; Elaine S Jaffe; Randy D Gascoyne; Sandeep S Dave; Hans-Konrad Mueller-Hermelink; Louis M Staudt; German Ott; Sílvia Beà; Andreas Rosenwald
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

Review 8.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

9.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2008-09       Impact factor: 0.196

10.  Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.

Authors:  Krithika Shanmugasundaram; Subir Goyal; Jeffery Switchenko; Oscar Calzada; Michael C Churnetski; Bhaskar Kolla; Veronika Bachanova; James N Gerson; Stefan K Barta; Max J Gordon; Alexey V Danilov; Natalie S Grover; Stephanie Mathews; Madelyn Burkart; Reem Karmali; Yazeed Sawalha; Brian T Hill; Nilanjan Ghosh; Steven I Park; Narendranath Epperla; David A Bond; Talha Badar; Kristie A Blum; Mehdi Hamadani; Timothy S Fenske; Mary Malecek; Brad S Kahl; Peter Martin; Jin Guo; Christopher R Flowers; Jonathon B Cohen
Journal:  Eur J Haematol       Date:  2021-06-17       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.